Phaseline

Companies › Bellus Health Inc. - a GSK company

Bellus Health Inc. - a GSK company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Respiratory; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Camlipixant (BLU-5937)
P2X purinoceptor 3 antagonist
P2RX3Phase 3CoughMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05600777Camlipixant (BLU-5937)Phase 3CoughRespiratoryMar 2027

Targets

P2RX3 (1)

Companies with the same targets

GSK

Companies built like this

Kringle Pharma Biotest Areteia Therapeutics PureTech Renovion

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.